Are the Newer Carbapenems of Any Value against Tuberculosis

Our aim was to assess whether newer carbapenems with a better administration profile than meropenem (ertapenem, faropenem and tebipenem) were more effective against Mycobacterium tuberculosis including M/XDRTB and determine if there was a synergistic/antagonistic effect with amoxicillin or clavulana...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalo, Ximena, Drobniewski, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404707/
https://www.ncbi.nlm.nih.gov/pubmed/36009939
http://dx.doi.org/10.3390/antibiotics11081070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404707/
https://www.ncbi.nlm.nih.gov/pubmed/36009939
http://dx.doi.org/10.3390/antibiotics11081070

Ejemplares similares